Pfizer and BioNTech reportedly said that their COVID-19 vaccine “can stand warmer temperatures”.
Pfizer and BioNTech on Friday said that their COVID-19 vaccine “can stand warmer temperatures”, according to a report.
In a report on GMA News Online, Pfizer and BioNTech said that tests had shown that their COVID-19 vaccine can stand warmer temperatures than initially thought, potentially simplifying the vaccine’s complex cold-chain logistics.
Pfizer and BioNTech said that they had asked the United States Food and Drug Administration (US FDA) to allow for the COVID-19 vaccine to be stored for up to two weeks at -25°C to -15°C (-13°F to +5°F) — temperatures commonly found in pharmaceutical freezers and refrigerators.
Under the existing guidelines, however, the Pfizer-BioNTech COVID-19 vaccine needed to be stored at -80°C to -60°C until 5 days before use, a delicate process that required “special ultra-cold containers” for shipping and dry ice for storage.
As per the report, Pfizer CEO Albert Bourla said in a statement that if approved, the said new storage option would offer vaccination centers and pharmacies greater flexibility in how they managed their vaccine supply.
In a separate report on Inquirer, Pfizer and BioNTech said that they had submitted new data to the US FDA showing the stability of their COVID-19 vaccine at temperatures commonly found in refrigerators and pharmaceutical freezers.